C K Ramesan, Thomas Vinotha, Thomas Dhanya Susan, Daniel Sherin, Sebastian Ajit, Thomas Anitha, Chandy Rachel George, Peedicayil Abraham
Department of Gynaecologic Oncology, Christian Medical College, Vellore, Vellore, Tamil Nadu 632004 India.
Department of General Pathology, Christian Medical College, Vellore, Vellore, Tamil Nadu India.
Indian J Surg Oncol. 2021 Mar;12(1):152-157. doi: 10.1007/s13193-020-01267-4. Epub 2021 Jan 7.
The ovary is a common site of metastasis. Differential diagnosis of ovarian carcinomas, including secondary tumors, remains a challenging task. Clinical decision-making depends on an accurate diagnosis of the type of ovarian cancer. This study was done to evaluate the pattern of metastatic tumors to the ovary and clinical details and to analyze the survival outcomes over a period of 5 years. Patients who had metastatic tumors to the ovary are identified from the electronic database from 1 January 2015 to 30 September 2019. Clinical details are collected from the electronic charts. Survival data is collected over the phone. The total number of ovarian cancers treated during the time period was 720, of which primary high-grade mucinous tumors contributed 9 (1.2%), and metastatic tumors to ovary 70 (10%). The highest levels of CEA were seen in carcinoma rectum, colon, and cholangiocarcinoma. CA 19-9 was very high in carcinoma gall bladder, pancreas, and cholangiocarcinoma. Common primaries were stomach (23%), gall bladder (13%), and colon (13%). Adenocarcinoma with signet ring cells was found in 29% of the patients. The median follow-up was 7 months (range 1 to 40 months). The median overall survival was 10 months after diagnosis (95% CI,7.9-12.0). There was no statistically significant difference in survival between patients who had peritoneal carcinomatosis with enlarged ovaries and those who had metastasis confined to ovaries ( value 0.360). A diagnosis of metastatic tumors to the ovary is associated with a very poor prognosis and the focus of treatment should be to improve the quality of life.
The online version contains supplementary material available at 10.1007/s13193-020-01267-4.
卵巢是常见的转移部位。卵巢癌的鉴别诊断，包括继发性肿瘤，仍然是一项具有挑战性的任务。临床决策取决于对卵巢癌类型的准确诊断。本研究旨在评估卵巢转移性肿瘤的模式、临床细节，并分析5年期间的生存结果。从2015年1月1日至2019年9月30日的电子数据库中识别出患有卵巢转移性肿瘤的患者。临床细节从电子病历中收集。生存数据通过电话收集。在此期间接受治疗的卵巢癌总数为720例，其中原发性高级别黏液性肿瘤占9例（1.2%），卵巢转移性肿瘤占70例（10%）。癌胚抗原（CEA）水平在直肠癌、结肠癌和胆管癌中最高。糖类抗原19-9（CA 19-9）在胆囊癌、胰腺癌和胆管癌中非常高。常见的原发部位是胃（23%）、胆囊（13%）和结肠（13%）。29%的患者发现印戒细胞腺癌。中位随访时间为7个月（范围1至40个月）。诊断后中位总生存期为10个月（95%可信区间，7.9 - 12.0）。有腹膜癌伴卵巢肿大的患者与转移局限于卵巢的患者在生存方面无统计学显著差异（P值0.360）。卵巢转移性肿瘤的诊断与非常差的预后相关，治疗重点应是提高生活质量。
在线版本包含可在10.1007/s13193-020-01267-4获取的补充材料。
